188 related articles for article (PubMed ID: 37382635)
21. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
22. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of role of Notch3 signaling pathway in human lung cancer cells.
Hassan WA; Yoshida R; Kudoh S; Motooka Y; Ito T
J Cancer Res Clin Oncol; 2016 May; 142(5):981-93. PubMed ID: 26838758
[TBL] [Abstract][Full Text] [Related]
24. An EGFR-mutant lung adenocarcinoma that transformed into small-cell lung cancer. A case report.
Chowaniecova G; Berzinec P; Kosturiakova G; Plank L; Farkasova A; Sekeresova M; Juskanic D; Ondrus D
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Dec; 166(4):451-454. PubMed ID: 36036563
[TBL] [Abstract][Full Text] [Related]
25. Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.
Augert A; Eastwood E; Ibrahim AH; Wu N; Grunblatt E; Basom R; Liggitt D; Eaton KD; Martins R; Poirier JT; Rudin CM; Milletti F; Cheng WY; Mack F; MacPherson D
Sci Signal; 2019 Feb; 12(567):. PubMed ID: 30723171
[TBL] [Abstract][Full Text] [Related]
26. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.
Ogino A; Choi J; Lin M; Wilkens MK; Calles A; Xu M; Adeni AE; Chambers ES; Capelletti M; Butaney M; Gray NS; Gokhale PC; Palakurthi S; Kirschmeier P; Oxnard GR; Sholl LM; Jänne PA
Mol Oncol; 2021 Jan; 15(1):27-42. PubMed ID: 32191822
[TBL] [Abstract][Full Text] [Related]
27. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
Peters S; Trigo J; Besse B; Moreno V; Navarro A; Eugenia Olmedo M; Paz-Ares L; Grohé C; Antonio Lopez-Vilariño J; Fernández C; Kahatt C; Alfaro V; Nieto A; Zeaiter A; Subbiah V
Lung Cancer; 2024 Feb; 188():107448. PubMed ID: 38198859
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review.
Rajput PS; Khan SR; Singh P; Chawla PA
Anticancer Agents Med Chem; 2022; 22(5):812-820. PubMed ID: 34229593
[TBL] [Abstract][Full Text] [Related]
29. Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.
Ramkumar K; Tanimoto A; Della Corte CM; Stewart CA; Wang Q; Shen L; Cardnell RJ; Wang J; Polanska UM; Andersen C; Saeh J; Pease JE; Travers J; Fabbri G; Gay CM; Urosevic J; Byers LA
Clin Cancer Res; 2023 Aug; 29(16):3237-3249. PubMed ID: 37289191
[TBL] [Abstract][Full Text] [Related]
30. Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report.
Xie Z; Gu Y; Lin X; Ouyang M; Qin Y; Zhang J; Liu J; Mai S; Zhou C
Cancer Biol Ther; 2019; 20(9):1172-1175. PubMed ID: 31161851
[TBL] [Abstract][Full Text] [Related]
31. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
[TBL] [Abstract][Full Text] [Related]
32. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer.
Patel S; Petty WJ; Sands JM
Ther Adv Med Oncol; 2021; 13():17588359211020529. PubMed ID: 34104228
[TBL] [Abstract][Full Text] [Related]
33. Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.
Rittberg R; Leung B; Al-Hashami Z; Ho C
Curr Oncol; 2022 Dec; 29(12):9744-9752. PubMed ID: 36547179
[TBL] [Abstract][Full Text] [Related]
34. Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting.
Badin F
Cancer Treat Res Commun; 2024; 39():100803. PubMed ID: 38490092
[TBL] [Abstract][Full Text] [Related]
35. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.
Tripathi SC; Fahrmann JF; Celiktas M; Aguilar M; Marini KD; Jolly MK; Katayama H; Wang H; Murage EN; Dennison JB; Watkins DN; Levine H; Ostrin EJ; Taguchi A; Hanash SM
Cancer Res; 2017 Aug; 77(16):4414-4425. PubMed ID: 28646020
[TBL] [Abstract][Full Text] [Related]
36. Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer.
Hanvesakul R; Rengarajan B; Naveh N; Boccuti A; Park JE; Adeyemi A; Caisip C; Jansen JP; Wilson FR
J Comp Eff Res; 2023 May; 12(5):e220098. PubMed ID: 37079341
[No Abstract] [Full Text] [Related]
37. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
[TBL] [Abstract][Full Text] [Related]
38. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
Toublanc AC; Guecamburu M; Veillon R; Rosellini P; Girodet PO; Zysman M
Thorac Cancer; 2022 Aug; 13(15):2248-2252. PubMed ID: 35715960
[TBL] [Abstract][Full Text] [Related]
39. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.
Zhang CY; Sun H; Su JW; Chen YQ; Zhang SL; Zheng MY; Li YF; Huang J; Zhang C; Tai ZX; Cai M; Zhang XC; Su J; Xu CR; Yan HH; Chen HJ; Wu YL; Yang JJ
Lung Cancer; 2023 Jan; 175():68-78. PubMed ID: 36473332
[TBL] [Abstract][Full Text] [Related]
40. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.
Huang J; Cao D; Sha J; Zhu X; Han S
Biochem Biophys Res Commun; 2019 Jun; 514(3):853-860. PubMed ID: 31079917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]